» Articles » PMID: 32849500

Role of Cystic Fibrosis Bronchial Epithelium in Neutrophil Chemotaxis

Overview
Journal Front Immunol
Date 2020 Aug 28
PMID 32849500
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

A hallmark of cystic fibrosis (CF) chronic respiratory disease is an extensive neutrophil infiltrate in the mucosa filling the bronchial lumen, starting early in life for CF infants. The genetic defect of the CF Transmembrane conductance Regulator (CFTR) ion channel promotes dehydration of the airway surface liquid, alters mucus properties, and decreases mucociliary clearance, favoring the onset of recurrent and, ultimately, chronic bacterial infection. Neutrophil infiltrates are unable to clear bacterial infection and, as an adverse effect, contribute to mucosal tissue damage by releasing proteases and reactive oxygen species. Moreover, the rapid cellular turnover of lumenal neutrophils releases nucleic acids that further alter the mucus viscosity. A prominent role in the recruitment of neutrophil in bronchial mucosa is played by CF bronchial epithelial cells carrying the defective CFTR protein and are exposed to whole bacteria and bacterial products, making pharmacological approaches to regulate the exaggerated neutrophil chemotaxis in CF a relevant therapeutic target. Here we revise: (a) the major receptors, kinases, and transcription factors leading to the expression, and release of neutrophil chemokines in bronchial epithelial cells; (b) the role of intracellular calcium homeostasis and, in particular, the calcium crosstalk between endoplasmic reticulum and mitochondria; (c) the epigenetic regulation of the key chemokines; (d) the role of mutant CFTR protein as a co-regulator of chemokines together with the host-pathogen interactions; and (e) different pharmacological strategies to regulate the expression of chemokines in CF bronchial epithelial cells through novel drug discovery and drug repurposing.

Citing Articles

Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol.

Swenson C, Hunt W, Manfredi C, Beltran D, Hong J, Davis B PLoS One. 2025; 20(2):e0316721.

PMID: 39951444 PMC: 11828409. DOI: 10.1371/journal.pone.0316721.


Lung-Kidney Axis in Cystic Fibrosis: Early Urinary Markers of Kidney Injury Correlate with Neutrophil Activation and Worse Lung Function.

Rosner G, Goswami H, Sessions K, Mendyka L, Kerin B, Vlasac I medRxiv. 2024; .

PMID: 39371147 PMC: 11451629. DOI: 10.1101/2023.11.10.23298378.


Leveraging Tunable Nanoparticle Surface Functionalization to Alter Cellular Migration.

Tetrick M, Murphy C ACS Nanosci Au. 2024; 4(3):205-215.

PMID: 38912285 PMC: 11192187. DOI: 10.1021/acsnanoscienceau.3c00055.


CFTR dysfunction leads to defective bacterial eradication on cystic fibrosis airways.

Wu M, Chen J Front Physiol. 2024; 15:1385661.

PMID: 38699141 PMC: 11063615. DOI: 10.3389/fphys.2024.1385661.


Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies.

Carbone A, Vitullo P, Di Gioia S, Conese M Genes (Basel). 2023; 14(10).

PMID: 37895314 PMC: 10606852. DOI: 10.3390/genes14101966.


References
1.
Zhou Y, Song K, Painter R, Aiken M, Reiser J, Stanton B . Cystic fibrosis transmembrane conductance regulator recruitment to phagosomes in neutrophils. J Innate Immun. 2013; 5(3):219-30. PMC: 3717385. DOI: 10.1159/000346568. View

2.
McNamara N, Gallup M, Sucher A, Maltseva I, McKemy D, Basbaum C . AsialoGM1 and TLR5 cooperate in flagellin-induced nucleotide signaling to activate Erk1/2. Am J Respir Cell Mol Biol. 2006; 34(6):653-60. PMC: 2644226. DOI: 10.1165/rcmb.2005-0441OC. View

3.
DORING G . The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med. 1994; 150(6 Pt 2):S114-7. DOI: 10.1164/ajrccm/150.6_Pt_2.S114. View

4.
Prandini P, De Logu F, Fusi C, Provezza L, Nassini R, Montagner G . Transient Receptor Potential Ankyrin 1 Channels Modulate Inflammatory Response in Respiratory Cells from Patients with Cystic Fibrosis. Am J Respir Cell Mol Biol. 2016; 55(5):645-656. DOI: 10.1165/rcmb.2016-0089OC. View

5.
Bezzerri V, Borgatti M, Nicolis E, Lampronti I, Dechecchi M, Mancini I . Transcription factor oligodeoxynucleotides to NF-kappaB inhibit transcription of IL-8 in bronchial cells. Am J Respir Cell Mol Biol. 2008; 39(1):86-96. DOI: 10.1165/rcmb.2007-0176OC. View